.22 mg semaglutide Once-weekly 2.4 led to significant decreases in body weight and fat mass over 12 months while preserving lean mass and improved muscle function in adults with obesity. Weight and fat behavior change Prescription Wegovy (Semaglutide) Ohio |

B12 deficiency, which semaglutide can worsen through reduced intrinsic factor production, causes digestive dysfunction that can amplify GI symptoms including burping

Tirzepatide is another useful drug for the treatment of obesity commercialised under the name Mounjaro which has later appeared to increase the arsenal of useful drugs for the treatment of obesity and marketed in Spain from 1 July 2024

it reflects the drug's stimulant pharmacology and the way appetite-suppressant effects tend to wane over time

1, 2024 from Davies, M., Frch, L., Jeppesen, O

In the first few weeks of treatment, some individuals may experience mild gastrointestinal side effects such as nausea, bloating, or occasional diarrhea